IDiyas

For the Inventor, By the Inventor

Robbinsville, NJ, United States of America

Cullen L Cavallaro

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal17 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents

Years Active: 2008-2018

Loading Chart...
Loading Chart...
17 patents (USPTO):
1. 10112936 - Five-membered heterocycles useful as serine protease inhibitors (2018-10-30),
2. 9617224 - Five-membered heterocycles useful as serine protease inhibitors (2017-04-11),
3. 9249096 - Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors (2016-02-02),
4. 9120794 - Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors (2015-09-01),
5. 9079860 - Five-membered heterocycles useful as serine protease inhibitors (2015-07-14),
6. 8952180 - Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors (2015-02-10),
7. 8716492 - Five-membered heterocycles useful as serine protease inhibitors (2014-05-06),
8. 8609664 - Piperazinyl derivatives as modulators of chemokine receptor activity (2013-12-17),
9. 8604056 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2013-12-10),
10. 8252830 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2012-08-28),
11. 8101778 - Five-membered heterocycles useful as serine protease inhibitors (2012-01-24),
12. 7985861 - Piperidinyl derivatives as modulators of chemokine receptor activity (2011-07-26),
13. 7842708 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2010-11-30),
14. 7626039 - Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2009-12-01),
15. 7615556 - Piperazinyl derivatives as modulators of chemokine receptor activity (2009-11-10),

Title: Innovations of Cullen L Cavallaro

Introduction

Cullen L Cavallaro is a prominent inventor based in Robbinsville, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of serine protease inhibitors. With a total of 17 patents to his name, Cavallaro's work has the potential to impact the treatment of thrombotic and inflammatory disorders.

Latest Patents

Cavallaro's latest patents focus on five-membered heterocycles that are useful as serine protease inhibitors. These inventions provide methods for treating thrombotic or inflammatory disorders by administering a therapeutically effective amount of specific compounds. The compounds of Formula (I) are designed to selectively inhibit serine protease enzymes involved in the coagulation cascade, such as thrombin and factor Xa. This innovative approach aims to improve therapeutic outcomes for patients suffering from related conditions.

Career Highlights

Cavallaro is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His expertise in the pharmaceutical industry has allowed him to contribute to groundbreaking innovations that address critical health issues.

Collaborations

Cavallaro has worked alongside notable colleagues, including Mimi Lifen Quan and Joanne M Smallheer. These collaborations have fostered a productive environment for innovation and have led to the successful development of new therapeutic compounds.

Conclusion

Cullen L Cavallaro's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in the treatment of thrombotic and inflammatory disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…